



## Letter to the Editor

### Examining the effect of a mindfulness based program for the improvement of cognitive function in an early stage of schizophrenia. A random controlled trial



Dear Editor,

Mindfulness based interventions (MBIs) are standardized group programs used in clinical and health contexts. In psychosis three meta-analyses that considered only RCTs suggested that MBIs have an effect on psychotic symptoms as primary outcome, with a greater effect on negative rather than positive symptoms (Khoury et al., 2013; Jansen et al., 2020; Louise et al., 2018). However, their effect on a fundamental element of schizophrenia such as Cognitive Impairments (CI) has not been explored. CI has been described as a core element that evolves during and after the course of the illness (Kelleher et al., 2013). Several authors have found that people after a first psychotic episode exhibit worsened cognitive functioning compared to control groups (e.g. Aas et al., 2014). MBIs have shown promising effects on cognitive functions in the general population, such as improvements in working memory and attention (for a review, see Raffone and Srinivasan, 2017) and even in social cognition in outpatients with chronic schizophrenia (Mediavilla et al., 2019). In this study, we propose to test the effect of eight sessions of adapted MBIs for psychosis in patients with early onset schizophrenia. Specifically, we measured cognitive functions as primary outcome.

A single-blind, multicenter randomized controlled trial (registration number ISRCTN24327446) with pre post treatment and 3-month follow-up measures was designed. A parallel group randomized at 1:1 was selected. The study was approved by three ethical committees (e.g. Public Health Service in Valdivia).

All patients were diagnosed with early onset schizophrenia or its subtypes according to the DSM-IV-TR. The primary clinical diagnoses were schizophrenia (69.6%), schizoaffective disorder (7.1%), and schizotypal disorder (3.6%). For the inclusion and exclusion criteria see Langer et al. (2017). Sample size was originally calculated including two samples: at risk mental state (ARMS) and first episode of psychosis (FEP) (Langer et al., 2017); however, it was not possible to include the ARMS sample in this project. The MATRICS Consensus Cognitive Battery [MCCB] was used to test cognitive functions. In a simple randomization process participants were assigned to receive either mindfulness therapy (eight sessions, 1,5 h each, once a week), according to the standard training of Mindfulness Based Cognitive Therapy (MBCT; Segal et al., 2002) and adapted for patients with psychosis (Chadwick et al., 2005), alongside treatment as usual (MT + TAU) or TAU (TAU; i.e., pharmacological and psychosocial intervention).

First, multiple independent Welch *t*-tests were performed to evaluate possible differences between groups (MT and TAU) prior to the beginning of the intervention. Second, 2 × 2 mixed ANOVAs were

conducted between subject variable Group (MT, TAU) and repeated measure variable Time (Pre, Post & Pre, Follow-up). Effect size is reported using Partial Eta Squared ( $\eta_p^2$ ).

Participants were recruited through 4 clinical centers that participated in the study. This process yielded 70 candidates (see Fig. 1 for the consort diagram trial profile). Finally, 45 participants between 16 and 36 years of age met the inclusion criteria and the baseline assessments. No group differences were observed in the participants' age, sex or years of schooling (MT;  $M = 24.0$ ,  $SD = 4.98$ , 62.5% male; TAU;  $M = 23.6$ ,  $SD = 45.75$ , 95.2% male). The dropouts are detailed in Fig. 1.

Regarding the cognitive areas of interest in the study, we focused first on the Attention/Vigilance, Working Memory, and Social Cognition dimensions of the MATRICS. At Post-treatment, we found that neither Working Memory nor Social Cognition showed significant main effects or interactions. The Attention/Vigilance domain showed a significant Time main effect ( $F(1,33) = 12.20$ ,  $p < .01$ ,  $\eta_p^2 = 0.06$ ), without a significant Group main effect or Group × Time interaction. Similar results were found on the overall Composite Cognitive Score ( $F(1,33) = 7.87$ ,  $p < .01$ ,  $\eta_p^2 = 0.01$ ) and the Speed of Processing Domain ( $F(1,33) = 4.40$ ,  $p < .05$ ,  $\eta_p^2 = 0.02$ ) (for the rest of the dimensions see Supplementary data). At 3-month follow-up, the mixed ANOVA showed no significant main effects or interactions in the Attention/Vigilance and Working Memory domains, but we found a significant Group main effect in the Social Cognition domain ( $F(1,24) = 5.00$ ,  $p < .01$ ,  $\eta_p^2 = 0.01$ ), without significant interaction. However, after excluding cases due to missing data at follow-up, baseline Social Cognition differed between groups ( $t = 2.45$ ,  $df = 22.3$ ,  $p = .02$ ). Furthermore, we found a significant Time main effect on the Speed of Processing domain ( $F(1,24) = 6.78$ ,  $p = .01$ ,  $\eta_p^2 = 0.01$ ).

Results show that MT and TAU produce the same positive effects on Attention/Vigilance, Speed of Processing and general cognitive functioning. At follow-up, the effect of MT and TAU on Speed of Processing was preserved. Given the novelty of this research, a direct comparison with previous studies was not possible. Nevertheless, a meta-analysis of the effect of Cognitive Remediation on cognitive functions in early schizophrenia found similar outcomes. Specifically, CR did not have a significant effect on global cognition and only the verbal learning domain of the MATRICS showed a significant improvement in comparison with the control groups (Revell et al., 2015). Relevant limitations should be noted and considered as part of the context of these findings. The sample size was small. The original recruitment target estimated was not achieved and this had a direct impact on the statistical power. We used simple randomization without stratification; thus, confounding variables in cognitive functions such as the prescription and dose of antipsychotic medications were not controlled.

In conclusion, eight MBIs sessions adapted for psychosis but not specific for cognitive impairments may not be enough to achieve significant effects on cognitive dimensions. Therefore, at least twelve sessions of MBIs tested in larger samples are recommended in order to confirm to what extent mindfulness does or does not have a differentiating effect on cognitive functions (Chien et al., 2019). Moreover, this is the first




Fig.1. Flow Diagram random controlled trial

Fig. 1. Flow diagram random controlled trial.

study to apply mindfulness in schizophrenia in Latin America confirming its feasibility and acceptability, giving cross-cultural validity to mindfulness as a non-harmful intervention.

#### Acknowledgements

This project was funded in Chile by ANID, Chilean National Research and Development Agency, (FONDECYT project number – No 11150846), and supported by ANID - Millennium Science Initiative, grant “Millennium Nucleus to Improve the Mental Health of Adolescents and Youths, Imhay,” and grant “Millennium Institute for Research in Depression and Personality, Midap”.

We would like to thank to the participants and their families for trusting in this project, as well as the clinicians involved in each clinical center where this study was conducted.

#### Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.schres.2020.07.012>.

#### References

- Aas, M., Dazzan, P., Mondelli, V., Melle, I., Murray, R.M., Pariante, C.M., 2014. A systematic review of cognitive function in first-episode psychosis, including a discussion on childhood trauma, stress, and inflammation. *Front. Psychiatry* 4, 182.
- Chadwick, P., Taylor, K.N., Abba, N., 2005. Mindfulness groups for people with psychosis. *Behav. Cogn. Psychother.* 33, 351–359.
- Chien, W.T., Cheng, H.Y., McMaster, T.W., Yip, A.L.K., Wong, J.C.L., 2019. Effectiveness of a mindfulness-based psychoeducation group programme for early-stage schizophrenia: an 18-month randomised controlled trial. *Schizophr. Res.* 212, 140–149.
- Jansen, J.E., Gleeson, J., Bendall, S., Rice, S., Alvarez-Jimenez, M., 2020. Acceptance- and mindfulness-based interventions for persons with psychosis: a systematic review and meta-analysis. *Schizophr. Res.* 215, 25–37.

- Kelleher, I., Clarke, M.C., Rawdon, C., Murphy, J., Cannon, M., 2013. Neurocognition in the extended psychosis phenotype: performance of a community sample of adolescents with psychotic symptoms on the MATRICS neurocognitive battery. *Schizophr. Bull.* 39, 1018–1026.
- Khoury, B., Lecomte, T., Gaudiano, B.A., Paquin, K., 2013. Mindfulness interventions for psychosis: a meta-analysis. *Schizophr. Res.* 150, 176–184.
- Langer, Á.I., Schmidt, C., Mayol, R., Díaz, M., Lecaros, J., Krogh, E., ... Gaspar, P.A., 2017. The effect of mindfulness based intervention in cognitive functions and psychological well-being applied as an early intervention in schizophrenia and high risk mental state in a Chilean sample: study protocol for a randomized controlled trial. *Trials* 18, 233.
- Louise, S., Fitzpatrick, M., Strauss, C., Rossell, S.L., Thomas, N., 2018. Mindfulness- and acceptance-based interventions for psychosis: our current understanding and a meta-analysis. *Schizophr. Res.* 192, 57–63.
- Mediavilla, R., Muñoz-Sanjose, A., Rodriguez-Vega, B., Bayon, C., Lahera, G., Palao, A., Bravo, M.F., 2019. Mindfulness-based social cognition training (SocialMind) for people with psychosis: a feasibility trial. *Front. Psychiatry* 10, 299.
- Raffone, A., Srinivasan, N., 2017. Mindfulness and cognitive functions: toward a unifying neurocognitive framework. *Mindfulness* 8, 1–9.
- Revell, E.R., Neill, J.C., Harte, M., Khan, Z., Drake, R.J., 2015. A systematic review and meta-analysis of cognitive remediation in early schizophrenia. *Schizophr. Res.* 168, 213–222.
- Segal, Z.V., Williams, J.M.G., Teasdale, J.D., 2002. *Mindfulness Based Cognitive Therapy for Depression: A New Approach to Preventing Relapse*. Guilford, New York.

Álvaro I. Langer  
 Mind-Body Lab, Instituto de Estudios Psicológicos, Facultad de Medicina,  
 Universidad Austral de Chile, Valdivia, Chile  
 Millennium Nucleus to Improve the Mental Health of Adolescents and  
 Youths (Imhay), Santiago, Chile  
 Millennium Institute for Research in Depression and Personality (MIDAP),  
 Santiago, Chile  
 Center for Interdisciplinary Studies on the Nervous System (CISNe),  
 Universidad Austral de Chile, Valdivia, Chile  
 Corresponding author at: Instituto de Estudios Psicológicos, Facultad de  
 Medicina, Universidad Austral de Chile, Valdivia, Chile.  
 E-mail address: [alvaro.langer@uach.cl](mailto:alvaro.langer@uach.cl)

Carlos Schmidt  
*Millennium Institute for Research in Depression and Personality (MIDAP),  
Santiago, Chile  
Brain, Cognition and Behavior PhD Program, University of Barcelona, Spain*

Rodrigo Vergara  
*Departamento de Kinesiología, Facultad de Artes y Educación Física,  
Universidad Metropolitana de Ciencias de la Educación, Chile*

Rocío Mayol-Troncoso  
*Millennium Nucleus to Improve the Mental Health of Adolescents and  
Youths (Imhay), Santiago, Chile  
Clínica Psiquiátrica Universitaria, Hospital Clínico y Facultad de Medicina,  
Universidad de Chile, Chile*

Javiera Lecaros  
*Escuela de Psicología, Universidad Adolfo Ibáñez, Chile*

Edwin Krogh  
*Mind-Body Lab, Instituto de Neurociencias Clínicas, Facultad de Medicina,  
Universidad Austral de Chile, Chile*

Carolina Vergara  
*Servicio de Psiquiatría y Salud Mental Hospital El Pino, San Bernardo,  
Santiago, Chile*

Marcela Díaz  
*Clínica Psiquiátrica Universitaria, Hospital Clínico y Facultad de Medicina,  
Universidad de Chile, Chile*

Gerardo Rivera  
*Mind-Body Lab, Instituto de Estudios Psicológicos, Facultad de Medicina,  
Universidad Austral de Chile, Valdivia, Chile  
Mind-Body Lab, Instituto de Neurociencias Clínicas, Facultad de Medicina,  
Universidad Austral de Chile, Chile*

Rodrigo Aguirre-Baez  
*Mind-Body Lab, Instituto de Estudios Psicológicos, Facultad de Medicina,  
Universidad Austral de Chile, Valdivia, Chile*

Pablo A. Gaspar  
*Millennium Nucleus to Improve the Mental Health of Adolescents and  
Youths (Imhay), Santiago, Chile  
Clínica Psiquiátrica Universitaria, Hospital Clínico y Facultad de Medicina,  
Universidad de Chile, Chile  
Clínica Alemana de Santiago, RM, Chile  
Instituto Milenio de Neurociencias, BNI, RM, Chile*

3 June 2020